Global markets are wrestling with shifting inflation signals, changing central bank policies, tighter emissions rules and uneasy trade relations. That mix can unsettle many stocks, yet it often draws attention to large cap defensive stocks that focus on steady balance sheets, reliable dividends and lower volatility. This article looks at how the latest news backdrop connects with our Global Large Cap Defensive Stocks screener and why some investors are watching this space more closely. Read on to see three stocks from the list that appear positively exposed to these developments and how they might fit, or not fit, into your own risk comfort zone.

Gilead Sciences (GILD)

Overview: Gilead Sciences is a large global biopharmaceutical company that discovers, develops and sells medicines for serious conditions such as HIV, viral liver diseases, COVID-19, cancer and invasive fungal infections. Its portfolio includes well known HIV treatments, cell therapies and oncology drugs, along with a pipeline of new immunotherapies for hard to treat diseases.

Operations: Gilead generates about US$29.7b in revenue from discovering, developing and commercializing medicines, with roughly US$21.1b from the United States, US$5.1b from Europe and US$3.5b from the rest of the world.

Market Cap: US$162.8b

Gilead Sciences stands out in the defensive large cap space because it combines a broad portfolio in chronic HIV and oncology treatments with strong profitability, net margins around 31%, and a 2.5% dividend yield. The company is focusing on long acting HIV prevention and cancer therapies like Trodelvy, which could reshape its product mix as healthcare demand responds to policy shifts and market volatility. At the same time, high debt, heavy reliance on HIV therapies and future patent expiries keep execution and regulatory risk front of mind, especially with Medicare reforms and tariff discussions in play. For investors reviewing how these factors align with detailed forecasts, capital allocation and risk indicators, understanding these dynamics can be important.

Gilead Sciences looks like a profit engine. Its HIV and oncology focus could be masking a deeper story about balance sheet strength and funding capacity. Get the full picture in the Gilead Sciences financial health report

Sysco (SYY)

Overview: Sysco is a global foodservice distributor that supplies restaurants, hospitals, schools, hotels and other venues with frozen and fresh foods, beverages and a wide range of non food items such as packaging, tableware, kitchen equipment and cleaning supplies. The company operates across the U.S. and internationally through several segments that handle large scale sourcing, storage and delivery for the food away from home sector.

Operations: Sysco generates about US$66.0b in revenue from U.S. Foodservice Operations, International Foodservice Operations, SYGMA and Other segments, with U.S. Foodservice Operations contributing roughly US$58.2b.

Market Cap: US$40.6b

Sysco offers investors a classic defensive consumer staples profile, with essential services that tend to hold up when markets react to changing inflation signals and central bank moves. The company is working to improve its salesforce productivity, roll out pricing tools and expand fulfillment capacity, while also targeting meaningful cost savings to support earnings and cash flow. At the same time, reliance on external debt, thin net margins around 2.1% and exposure to fuel costs, tariffs and weak restaurant traffic keep risk firmly on the table. With analyst fair value estimates and DCF work suggesting material upside to the current share price, the key consideration is how these strengths and pressures balance out for Sysco over the next few years.

Sysco’s thin margins and debt load may be obscuring a much more interesting earnings story. See how its pricing tools, cost savings push and cash generation stack up in the analysis report for Sysco, including one risk that could flip the script

Cencora (COR)

Overview: Cencora is a global pharmaceutical distributor that sits between drug manufacturers and healthcare providers, sourcing and delivering medicines, vaccines and related services to hospitals, pharmacies, clinics and animal health customers in the U.S. and overseas.

Operations: Cencora generates most of its revenue from U.S. Healthcare Solutions at about US$296.6b, with International Healthcare Solutions contributing around US$31.9b, alongside smaller segment adjustments and eliminations.

Market Cap: US$60.0b

Cencora gives you broad exposure to the healthcare supply chain at a time when policy shifts, inflation trends and new drug pricing rules are reshaping how medicines move and get reimbursed. The company has grown earnings faster than many Healthcare peers, is investing heavily in digital tools and inventory systems, and is returning cash through dividends and a US$2.0b buyback program. Its P/E still sits around sector levels, while our model suggests the stock trades well below estimated fair value. The trade off is thin margins, high leverage and softer performance in some international logistics and consulting units. How those strengths and pressure points net out is what really matters for long term holders of Cencora.

Cencora’s earnings growth, digital push and US$2.0b buyback could be masking a very different risk reward profile. See how that story lines up with the analyst forecasts for Cencora

The three stocks in this article are only a starting point, and the full Global Large Cap Defensive Stocks screener has identified 19 more companies with stories that could be just as compelling as the ones you have just read. To pinpoint the highest conviction ideas, use Simply Wall St to filter the Global Large-Cap Defensive Stocks screener by the specific catalysts, financial health markers and dividend profiles that matter most to you.

Take Control of Your Investment Journey

If Sysco or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value the ideal entry point. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Alternatives Beyond Defensive Giants

Fresh stock ideas move quickly. Some gain breakout momentum while others get caught dropping off the radar. Scan these under the radar lists before the crowd shifts and consider your options.

• Identify high cash yield opportunities before income hunters rush in by scanning a curated list of dividend stocks using the 7 dividend fortresses.
• Track early technology momentum as robotics and automation reshape global supply chains with a focused group from the 36 robotics and automation stocks.
• Follow the energy transition story into electricity infrastructure and see which grid specialists gain traction first using the 36 power grid technology and infrastructure stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.